Efficacy of roxadustat for anaemia in kidney transplant recipients and its drug-drug interaction with tacrolimus: A retrospective cohort study.

For both groups, at all follow-up points, Hb levels increased significantly from baseline (all P < .05).

No liver/kidney adverse effects were observed in either group.

Tacrolimus exposure was unchanged in the rhEPO group, while in the ROX group, the C 0 increased significantly at 1 and 3 months (P < .05), and C 0 /D was prominently higher than baseline at 1, 3 and 6 months (P < .01).